Prognostic implications of PIK3CA amplification in curatively resected liposarcoma by 源�寃쎌떇 et al.
Oncotarget24549www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 17
Prognostic implications of PIK3CA amplification in curatively 
resected liposarcoma
Joo Hoon Kim1,*, Jae Seok Lee2,*, Eo Jin Kim2, Kyu Hyun Park3, Ki Hyang Kim4, 
Seong Yoon Yi5, Han Seong Kim6, Yong Jin Cho7, Kyoo-Ho Shin7, Joong Bae Ahn1, 
Hyuk Hu8, Kyung Sik Kim8, Young Deuk Choi9, Sunghoon Kim10, Young Han Lee11, 
Jin-Suck Suh11, Sung Hoon Noh8, Sun Young Rha1, Hyo Song Kim1
1 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 
Seoul, Korea
2Department of Pathology, Dongguk University College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea
3 Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine, 
Seoul, Korea
4Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
5Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Ilsan, Korea
6Department of Pathology, Ilsan Paik Hospital, Inje University College of Medicine, Ilsan, Korea
7Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea
8Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
9Department of Urology, Yonsei University College of Medicine, Seoul, Korea
10Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
11Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
*These authors have contributed equally to this work
Correspondence to:  Sun Young Rha, e-mail: rha7655@yuhs.ac
Hyo Song Kim, e-mail: hyosong77@yuhs.ac
Keywords: liposarcoma, PIK3CA, amplification, mutation
Received: January 05, 2016    Accepted: March 02, 2016    Published: March 21, 2016
ABSTRACT
Background: We investigated the epidemiologic characteristics and prognostic 
significance of PIK3CA mutations/amplifications in curative resected liposarcoma.
Patients and methods: A total of 125 liposarcoma tissue samples were collected 
over a 12-year period. PIK3CA mutations and gene copy number amplifications were 
analyzed by pyrosequencing and fluorescence in situ hybridization (FISH).
Results: Nine of the 105 liposarcomas (8.6%) had activating PIK3CA mutation. 
PIK3CA mutations were more frequent in myxoid/round cell and pleomorphic tumors 
compared with well-differentiated/dedifferentiated tumors (13.3% vs. 2.2%, 
P=0.043). In FISH PIK3CA analysis, copy number gain was detected in 14 of the 101 
tumors (13.9%): 11 (10.9%) tumors had increased gene copy number (polysomy) 
and 3 (3.0%) exhibited gene amplification. In survival analysis, patients with PIK3CA 
copy number gain had a worse prognosis compared to patients without PIK3CA 
amplification (median disease-free survival [DFS] 22.2 vs. 107.6 months p=0.005). 
By multivariate analysis, PIK3CA copy number gain was an independent prognostic 
factor for worse DFS (P=0.027; hazard ratio, 2.400; 95% confidence interval 1.105 
to 5.213). PIK3CA mutation was not associated with DFS and overall survival.
Conclusions: We demonstrated PIK3CA mutation and amplification in liposarcoma. 
PIK3CA copy number gain was an independent poor prognostic factor for DFS. Further 
studies are needed to evaluate the potential diagnostic and therapeutic role of PIK3CA 
mutations and amplifications in liposarcoma.
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INTRODUCTION
Soft tissue sarcoma (STS) is a heterogeneous disease 
with over 50 histologic subtypes, with various biological 
behaviors and genetic features [1]. In adults, liposarcoma 
is the most common type STS, representing 17–25% of the 
total cases [2]. Although surgical resection is the primary 
treatment for localized disease, many liposarcomas 
eventually progress to advanced disease that is either 
unresectable, metastatic, or both. For patients with those 
tumors, the mortality is high, and local and/or systemic 
tumor burden also results in significant morbidity [3].
For prognostic reasons, liposarcoma is subdivided 
into 5 subtypes by the World Health Organization 
classification: well-differentiated, myxoid/round 
cell, dedifferentiated, pleomorphic, and mixed-type 
liposarcoma [4]. Well-differentiated and myxoid 
liposarcoma are low-grade tumors, while dedifferentiated, 
round cell, and pleomorphic liposarcoma are high-grade 
tumors. Low-grade tumors have a low frequency of 
metastasis, and high-grade tumors often manifest with 
clinically aggressive behavior and distant metastasis. 
Besides the recognition of specific histologic subtypes, 
better understanding of distinct genetic and molecular 
aberrations is critical for therapeutic strategy.
The phosphatidylinositol-3-kinase (PI3K)-Akt-
mTOR signaling pathway plays a central role in regulating 
tumor cell metabolism and survival [5]. Activation of the 
PI3K pathway occurs upon engagement with mutated or 
amplified phosphatidylinositol-4,5-bisphosphate 3-Kinase, 
catalytic subunit Alpha (PIK3CA) gene It increases 
p110α expression, PI3K activation, and phosphorylation 
of downstream signaling molecules. Akt-PIK3CA gene 
amplification was found in 10–30% of non-small cell lung 
cancer, breast cancer, and colon cancer [6–8]. Activating 
somatic mutations were also identified in various solid 
tumors [9, 10]. Recently, PIK3CA mutation was reported 
in 12% and 18% of myxoid/round-cell liposarcoma, and 
it was associated with Akt activation and poor clinical 
outcome [11, 12]. Despite accumulating evidence of 
biological role, there have been few studies reporting the 
frequency of PIK3CA aberration (including mutations and 
amplifications) for all liposarcoma subtypes.
In this study, we evaluated the frequency of 
PIK3CA amplification and mutation in surgically 
resected liposarcoma. Furthermore, we also determined 
the prognostic impact of PIK3CA genetic aberration for 
liposarcoma patients.
RESULTS
Clinical and pathological features
A total of Korean 125 patients with liposarcoma 
who underwent curative resection were analyzed. The 
clinical characteristics such as gender, age, primary tumor 
site, histology, and tumor size are presented in Table 1. 
The median age at diagnosis was 52 years (range: 18–84 
years), and male was predominant (62.4%). The median 
tumor size was 14.1 cm, and one-third of all tumors 
were over 15 cm. Primary tumors mainly occurred in the 
extremities (n=61, 48.8%), with the other sites being the 
retroperitoneum/intra-abdominal region (n=35, 28.0%), 
inguinal area/genital organ (n=10, 8.0%), and other sites 
(n=19, 15.2%). The distribution of histologic subtypes 
were as follows: myxoid in 52 patients (41.6%), well-
differentiated in 45 patients (36.0%), pleomorphic in 10 
patients (8.0%), dedifferentiated in 9 patients (7.2%), and 
round cell in 9 patients (7.2%).
PIK3CA amplification
Of the 125 cases, 101 tumor samples were 
evaluable for PIK3CA FISH analysis. Based on PIK3CA 
gene expression values, tumors were categorized into 
three groups: (I) normal copy number, tumors with ≤2 
copies per cell with a PIK3CA/CEN3 ratio < 2.0; (II) 
polysomy, tumors with an average PIK3CA signal per 
nucleus 4.0 ≥ to > 2.0; and (III) amplification, tumors 
with >4 copies per cell and/or a PIK3CA/CEN3 ratio 
≥ 2.0. By these criteria, of the 101 cases, 14 tumors 
(13.9%) demonstrated copy number gain, 11 (10.9%) 
had polysomy, and 3 (3.0%) had gene amplification 
(Table 2, Figure 1). The median PIK3CA gene copy 
numbers were 2.3 (range, 2.1–2.6) and 6.5 (range, 5.0–
10.3) in PIK3CA the polysomy and amplification groups, 
respectively. We also analyzed the association between 
PIK3CA amplification status and clinical parameters. 
PIK3CA copy number gain was significantly associated 
with older age and larger tumor size (Table 1, P=0.023 
and P=0.040, respectively). There were no significant 
differences in PIK3CA copy number change with respect 
to sex, histology, and primary tumor site.
With a median follow-up time of 50.6 months, 
the 5-year DFS and OS rates were 57.9% and 82.8%, 
respectively. The PIK3CA copy number gain group 
(polysomy and amplification) had a significantly shorter 
DFS compared with that of normal group (Figure 2A, 
median 22.0 vs. 107.6 months, P=0.005). Using the Cox 
proportional hazard model adjusted for gender, age, 
histology, and tumor location, PIK3CA copy number 
gain was an independent poor prognostic factor for 
DFS (Table 3, P=0.027; hazard ratio [HR], 2.400; 95% 
confidence interval [CI] 1.105 to 5.213). Older age 
(p=0.013; HR, 2.393; 95% CI 1.203 to 4.760) was also an 
independent poor prognostic factor for DFS. There was no 
significant difference in OS with respect to PIK3CA copy 
number gain (P=0.144, Figure 2B)
PIK3CA mutation
Among the 125 patients, 105 tumor samples were 
available for PIK3CA mutation analysis. Activating 
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Table 1: Patient characteristics based on PIK3CA amplification
Characteristics All patients Copy number gain
(Polysomy + 
Amplification)*
Normal copy number P†
 
No. % No. % No. %
Number of patients 125 100 14 13.9 87 86.1  
Age, years
Median (range)
52 (18-84) 61 (37-84) 50 (20-83) 0.023
Gender    0.487
 Male 78 62.4 8 57.1 58 66.7
 
 Female 47 37.6 6 42.9 29 33.3
Tumor size, cm
Median (range)
14.1 (1.0-37.0) 18.5 (5.5-37.0) 12.25 (1.0-31.0) 0.040
 0-5 cm 19 15.2 0 0 16 18.4  
 5-10 cm 26 20.8 3 21.4 18 20.7  
 10-15 cm 26 20.8 1 7.1 20 30.0  
 >15 cm 46 36.8 8 57.1 28 32.2  
 unknown 8 6.4 2 14.3 5 5.7  
Histologic classification     0.063
 Well- and De-differentiated 54 43.2 9 64.3 33 37.9
   Well differentiated 45 36.0 7 50.0 30 34.5
  Dedifferentiated 9 7.2 2 14.3 3 3.4
  Mixoid/Round cell, 
Pleomorphic 71 58.8 5 35.7 54 62.1  
  Myxoid 52 41.6 2 14.3 44 50.6  
  Round cell 9 7.2 1 7.1 5 5.7  
  Pleomorphic 10 8.0 2 14.3 5 5.7  
Primary tumor site       0.051
 Extremity 61 48.8 4 28.6 46 52.9  
  Lower extremity 55 44.0 4 28.6 43 49.4  
  Upper extremity 6 4.8 0 0 3 3.4  
  Retroperitoneum/
intraabdomen 35 28.0 8 57.1 18 20.7  
  Retroperitoneum 27 21.6 5 35.7 15 17.2  
  Intraabdomen 8 6.4 3 21.4 3 3.4  
 Inguinal area & genital organ 10 8.0 1 7.1 8 9.2  
 Other area 19 15.2 1 7.1 15 17.2  
Time to recurrence, months
Median (range)
22.0 (3.7-240.9) 13.8 (6.2-95.2) 34.4 (3.7-240.9)  
Abbreviations: PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-Kinase, Catalytic Subunit Alpha;CEN3, centromere3
*PIK3CA amplification was defined as if one of the following criteria is fulfilled: (1) PIK3CA/CEN3 ratio is ≥ 2.0, (2) 
average number of PIK3CA signal per nucleus > 4.0
*PIK3CA polysomy were defined as average number of PIK3CA signal per nucleus 4.0 ≥ to > 2.0.
†χ2 test, Fisher’s exact test, t-test or Mann-Whitney U test.
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Table 2: PIK3CA amplification status according to liposarcoma histologic subtype
Histologic classification Normal Copy  
Number
Copy Number Gain
Polysomy Amplification Total, n (%)
Well- and De-differentiated 33 6 3 9 (21.4)
 Well- differentiated 30 6 3  
 De-differentiated 3 0 0  
Myxoid/Round cell, Pleomorphic 54 5 0 5 (8.5)
 Myxoid/ Round cell 49 3 0  
 Pleomorphic 5 2 0  
Total, n (%) 87 (86.1)
11 (10.9) 3 (3.0)
 
14 (13.9)
Figure 1: Representative fluorescent in situ hybridization of tumors with A. normal copy numbers, B. polysomy, 
C. and PIK3CA amplification.
Figure 2: Survival analysis based on PIK3CA status. A. The median disease-free survival (DFS) was 22.0 months in patients with 
PIK3CA copy number gain and 107.6 months in the normal group. B. The median overall survival (OS) was not significantly different 
between the two groups.
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PIK3CA mutation was detected in 9 (8.6%) of 105 
cases, with 5 cases of exon 9 mutation and 4 cases of 
exon 20 mutation (Table 4). For PIK3CA exon 9, E542K 
mutations were identified in 2 tumors, Q546K mutations 
were identified in 2 tumors, and an E545K mutation was 
identified in 1 tumor. For exon 20, H1047R mutations 
were identified in 3 tumors, and an H1047L was identified 
in 1 tumor (Figure 3). There was no co-occurrence of exon 
9 and exon 20 mutations.
With respect to histologic subtype, PIK3CA 
mutations were more frequent in well-differentiated/
dedifferentiated tumors compared with myxoid/round 
cell/pleomorphic tumors (Table 4, 13.3% vs. 2.2%, 
P=0.043). Of all mutated tumors, 6 tumors (66.7%) were 
myxoid/round cell, 2 tumors (22.2%) were pleomorphic, 
and 1 tumor (11.1%) was well-differentiated (Table 4, 
Supplementary Table 1). There were no statistically 
significant differences in PIK3CA mutation based on sex, 
age, tumor size, and primary tumor sites (Supplementary 
Table 1). We also performed analyses to examine the 
association between PIK3CA mutations and survival 
outcome. PIK3CA mutation was not associated with 
a significant difference in DFS or OS (data not shown, 
p=0.739 and p=0.376, respectively)
Correlation between PIK3CA mutation and copy 
number status
There were 82 cases with complete data on PIK3CA 
mutation and copy number status (Supplementary 
Table 2). Although not statistically significant, PIK3CA 
mutations were more frequent in the cases of copy number 
gain. Of the 7 tumors with PIK3CA mutation, 3 tumors 
(21.4%) exhibited copy number gain, whereas only 4 
tumors (5.9%) had normal copy numbers.
DISCUSSION
We conducted this study to examine the frequency 
and prognostic impact of PIK3CA mutations and 
amplifications in patients with curatively resected 
liposarcoma. To our knowledge, this is the first study 
evaluating the prognostic impact of PIK3CA polysomy 
and amplification in a large cohort of Asian liposarcoma 
patients. We demonstrated that PIK3CA aberration is a 
poor prognostic factor in liposarcoma.
Accumulating evidence has suggested different 
outcomes for the major histologic subtypes of liposarcoma. 
Therefore, histologic classification is known as a most 
strong prognostic factor for survival [13–16]. Among the 
5 subtypes of liposarcoma, well-differentiated and myxoid 
liposarcoma had the most favorable prognoses, while 
dedifferentiated, round cell, and pleomorphic liposarcomas 
often manifest with clinically aggressive behavior and 
distant metastasis. Overall, with use of conventional 
doxorubicin-based chemotherapy, median survival 
remains less than 12 months for patients with metastatic/
unresectable tumors [17]. The limited improvement after 
conventional therapy treatment prompts us to explore the 
molecular biology and identify prognostic and druggable 
biomarkers.
Table 3: Prognostic factors for disease-free survival and overall survival
Variable Category DFS OS
HR 95% CI P HR 95% CI P
PIK3CA copy 
number status
Copy number gain vs
Normal copy number 
(ref)
2.400 1.105-5.213 0.027 1.628 0.555-4.770 0.375
Age Age ≥52 years vs
Age < 52 years (ref)
2.393 1.203-4.760 0.013 3.875 1.351-11.118 0.012
Gender Female vsMale (ref) 0.650 0.357-1.186 0.161 1.078 0.431-2.697 0.873
Histology
Mixoid/Round cell, 
Pleomorphic vs
Well/De-diff (ref)
1.692 0.896 -3.196 0.105 1.336 0.538-3.316 0.533
Primary tumor 
sites
Extremity, Inguinal/
genital, other area
vs Retroperitoneum/
Intraabdomen (ref)
0.880 0.439-1.762 0.718 1.335 0.420-4.242 0.624
Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ref, reference; 
diff, differentiated
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Table 4: PIK3CA mutational status according to liposarcoma histologic subtype
Histologic 
classification
Wild type Mutation
Exon 9 Exon 20 Total, n (%)
E542K E545K Q546K H1047R H1047L
Well- and De-
differentiated 44 0 0 0 1 0 1 (2.2)
  Well- 
differentiated     1 0 1
 De-differentiated     0 0  
Myxoid and Round 
cell, Pleomorphic 52 2 1 2 2 1 8 (13.3)
  Myxoid and 
Round cell 43 2 0 1 2 1 6
 Pleomorphic 9 0 1 1 0 0 2
Total, n (%) 96 (91.4)
5 (4.8) 4 (3.8)
P=0.043
9 (8.6)
Figure 3: PIK3CA mutations in liposarcoma detected by pyrosequencing. A. Wild-type and exon 9 E545K (G1633A) 
mutations. B. Wild-type and exon 20 H1047R (A3140G) mutations.
Oncotarget24555www.impactjournals.com/oncotarget
Despite known targeted therapeutic options in solid 
tumors (KIT or PDGFRA mutations in gastrointestinal 
stromal tumors), STS still lacks therapeutically relevant 
genetic alterations. Even knowledge of genetic alteration 
frequency is limited. A recent comprehensive genome 
study reported frequently mutated genes, including TP53, 
NF1, and PIK3CA, in STS [11]. Among them, PIK3CA 
mutation was observed in 18% of myxoid/round cell 
liposarcomas. Therefore, PIK3CA may be a putative driver 
gene in liposarcoma, with available therapeutic agents 
worthwhile.
Activation of the PI3K pathway, generally as result 
of PIK3CA amplification, has been demonstrated in 12% 
cases of lung cancer, 32% cases of head and neck cancer, 
and 24% cases of ovarian cancer [18–20]. Regarding 
the prognostic role of PIK3CA amplification, the results 
have been controversial. In head and neck squamous cell 
carcinoma, PIK3CA amplification led to earlier recurrence 
[18]. For nasopharyngeal carcinoma, amplification was 
associated with distant metastasis, advanced stage, and 
poor OS [21]. On the other hand, amplification played 
no significant role in squamous cell lung cancer cohort 
[8]. Clinicopathologic heterogeneity, including primary 
tumor site, pathologic stage, and adjuvant treatment, may 
contribute to these controversial results. However, because 
of its rarity of sarcoma, no exact frequency of PIK3CA 
amplification has been identified in sarcoma. Only The 
Cancer Genome Atlas (TCGA) data had reported 1% 
frequency of PIK3CA amplification and few comparable 
studies were reported with clinical cases. In our study, by 
carefully assessing a large cohort of liposarcoma cases, 
we were able to clarify the prognostic value of PIK3CA 
amplification in a homogenous patient population. 
PIK3CA amplification was significantly associated with 
poor DFS regardless of gender, age, histology, or tumor 
location, as an independent prognostic factor in curatively 
resected liposarcoma.
To evaluate PIK3CA copy number gain, we used 
FISH. Previous studies defined PIK3CA/CEP3≥2 [22–
24] as PIK3CA amplification, and some studies used 
PIK3CA>4 [18, 25]. In our large cohort study, we used 
a combination of these criteria and demonstrated that 
amplification and polysomy have significant prognostic 
impacts on liposarcoma patients. FISH is an easy and 
useful method by which one can visualize individual 
cancer cells in routine clinical practice. Our criteria need 
further validation in future clinical trials with targeted 
agents.
Mutations in the PIK3CA gene are mostly located 
within hotspots in exons 9 and 20 and lead to PI3K 
pathway activation [26]. Regarding the prognostic 
significance of PIK3CA mutation, previous reports 
yielded controversial results [6, 26–29]. PIK3CA 
mutation has been reported 14–18.3% of myxoid/round-
cell liposarcoma and associated with shorter DFS with 
mass spectrometry-based genotyping [11, 12]. Here, we 
report PIK3CA mutations in 8.6% of liposarcoma by 
employing a pyrosequencing approach and not associated 
with prognostic outcome. Although the majority of 
mutant tumors (66.6%) were of the myxoid/round-cell 
subtype, additional mutant cases were also detected in 
well-differentiated, dedifferentiated, and pleomorphic 
liposarcoma. The limited sensitivity of sequencing method 
may result in low frequency or clinical outcome and 
further studies are warranted.
Despite first-line standard treatment with 
doxorubicin, median survival remains dismal. gemcitabine 
and docetaxel are frequently used as second-line treatment 
for STS [30]. While the total response rate for all patients 
is 16%, only 2 out of 20 liposarcoma patients had stable 
disease at 6 months. Pazopanib was another potential 
breakthrough as a salvage treatment for STS [31]. 
However, pazopanib showed favorable efficacy in patients 
with leiomyosarcoma and synovial sarcoma, but not in 
adipocytic sarcoma [32]. Similar outcomes were observed 
in our Asian STS patients who received pazopanib 
treatment [33]. Therefore, exploration of therapeutically 
tractable target based on molecular biology is strongly 
warranted. Recently, local amplification of the 12q13-15 
regions, which contain copies of CDK4, was reported in 
well-differentiated liposarcoma [34]. However, because 
that subtype is relatively indolent and easily curable with 
surgical resection, CDK4 inhibitors are not necessary 
for treatment of well differentiated liposarcoma [16]. In 
our study, we found frequent aberrations of the PIK3CA 
gene mainly in the aggressive subtypes (round cell and 
pleomorphic), and it is worth considering as a therapeutic 
target.
PIK3CA amplification and/or mutation are 
associated with increased activity of the PI3K effector 
pAkt, suggesting that amplified or mutated tumors may 
be sensitive to PI3K inhibitors [22, 35]. In lung cancer 
cell lines, 37% of squamous cell harbored PIK3CA 
amplification and they were sensitive to PI3K inhibitor 
GDC-0941 with less than 1μmol/L of IC50 [35]. In a 
preclinical platform from Cancer Cell Line Encyclopedia, 
PIK3CA-amplified tumors were sensitive to BYL719, a 
PI3K α-selective inhibitor [36]. Cell lines with PIK3CA 
amplification was positively associated with BYL719 
sensitivity (P=0.0037) and tumor-bearing mice with 
PIK3CA amplification responded to BYL719, leading 
to a response rate of -18% (lung cancer) and -80% 
(gastric cancer). Despite preliminary data, recent phase 
I trials have explored the potential predictive role of the 
PIK3CA gene. In a phase I trial with GDC-0941, a heavily 
treated ovarian cancer patient with PIK3CA amplification 
experienced disease stabilization for 4 months with 
significant pharmacodynamic changes [37]. While 
previous trials with PI3K inhibitors have been conducted 
in non-selected patients, recent clinical trials with PI3K 
inhibitors are ongoing for those with PIK3CA gene 
alterations (ClinicalTrials.gov number NCT01928459 
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and NCT01608022). As shown in our study, liposarcoma 
may be a promising potential candidate for use of PI3K 
inhibitors. Further study with preclinical model is 
warranted to validate the therapeutic role in sarcoma.
Here, we report PIK3CA aberration as an 
independent poor prognostic factor for curatively resected 
liposarcoma. Our findings also indicate that PIK3CA 
inhibitor is a promising therapeutic target for liposarcoma.
MATERIALS AND METHODS
Patients and tumor tissues
This study was conducted in a cohort of patients 
with liposarcoma who underwent curative resection at 
Severance Hospital, Busan Paik Hospital, and Ilsan Paik 
Hospital. A total of 125 formalin-fixed, paraffin-embedded 
primary liposarcoma specimens were available for 
examination of PIK3CA aberrations. All diagnoses were 
reviewed by two experienced pathologists (LJS and HSK) 
in conjunction with immunohistochemical staining data. 
Only those cases of confirmed liposarcoma containing 
tissue adequate for analytic purposes were included. 
Liposarcoma was classified into 5 histologic subgroups 
based on Evans Classification [38]: well-differentiated, 
myxoid, dedifferentiated, round, and pleomorphic.
Patient information was collected by reviewing 
the medical records for evaluations of clinicopathologic 
characteristics and survival outcomes. Primary tumors 
were located in the extremity, retroperitoneum/intra-
abdominal region, inguinal area/genital organs, and other.
PIK3CA gene copy number analysis
To assess the presence of PIK3CA gene 
amplifications, fluorescent in situ hybridization (FISH) 
assays were performed using a PIK3CA probe that 
hybridizes to the band 3q26.32 with a Texas Red tag 
(red) and centromere3 (CEN3) with a FITC tag (green) 
(Abbott Molecular, Abbott Park, IL), according to routine 
methods. At least 60 nuclei were evaluated per sample. 
Twenty contiguous tumor cell nuclei were analyzed 
from three representative foci. PIK3CA amplification 
was defined based on previous studies [22, 23, 25, 39]. 
PIK3CA amplification was defined as if one of the 
following criteria is fulfilled: (1) PIK3CA/CEN3 ratio was 
≥2.0 or (2) the average PIK3CA signal per nucleus >4.0. 
Polysomy was defined as an average PIK3CA signal per 
nucleus 4.0 ≥ to > 2.0.
PIK3CA mutational analysis
Genomic DNA was extracted from 125 formalin-
fixed paraffin-embedded (FFPE) tissue specimens 
using a QIAamp DNA FFPE Tissue Kit (Qiagen, 
Hilden, Germany), according to the manufacturer’s 
instructions. We used a pyrosequencing assay covering 
the mutational hotspots of interest to sequence exons 9 
and 20 of PIK3CA [40]. The exon 9 polymerase chain 
reaction (PCR) primers were PIK3CA 9-F, 5′-biotin-
AACAGCTCAAAGCAATTTCTACACG-3′, and 
PIK3CA 9-R, 5′-ACCTGTGACTCCATAGAAAATC
TTT-3′. The exon 20 PCR primers were PIK3CA 20-F, 
5′-biotin-CAAGAGGCTTTGGAGTATTTCA-3′, and 
PIK3CA 20-R, 5′-CAATCCATTTTTGTTGTCCA-3′. 
Each PCR mix contained the forward and reverse primers 
(10 μM each), 12.5 mM dNTP mix, 3 mM MgCl2, 1× 
PCR buffer, 1 U of AmpliTaq Gold, and 100 ng of sample 
genomic DNA in a total volume of 25 μL. PCR conditions 
were as follows: initial denaturation at 95°C for 5 minutes; 
50 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 
and 72°C for 40 seconds; and final extension at 72°C for 
10 minutes. The PCR products were electrophoresed in 
an agarose gel to confirm successful amplification. The 
PCR products were sequenced using the PyroMark Q24 
system (QIAGEN, Germantown, MD, USA), according to 
the manufacturer’s instructions. Sequencing analysis was 
performed using PyroMark Q24 software version 1.0.10 in 
the allele quantification analysis mode.
Statistical methods
Associations between histologic features and clinical 
significance were examined using the χ2 test or Fisher’s 
exact test where appropriate. Differences were statistically 
significant when the P-value was <0.05. Disease-free 
survival (DFS) was defined as the time from surgery to 
recurrence or last contact. Overall survival (OS) was 
defined as the time from surgery to death or last contact. 
Patients who were alive and had no recurrence at the last 
follow-up were censored. DFS and OS distributions were 
estimated using the Kaplan-Meier method. The log-rank 
test was used to determine survival differences between 
groups. Regression analyses of survival data, based on 
the Cox proportional hazards model, were conducted on 
DFS and OS. All data were analyzed using the Statistical 
Package for the Social Sciences Version 20.0 Software 
(SPSS Inc., Chicago, IL).
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